False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring <i>ATM</i> and <i>CHEK2</i> Mutations.
Where this comes from
- Record sourced from PubMed, PMID 39208375.
- Also identified by DOI 10.1200/PO.24.00354 and PMC identifier 11371381.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
False-positive ctDNA results do not explain lack of efficacy for PARPi in patients with ATMm and CHEK2m CRPC.
Medical subject headings
- Checkpoint Kinase 2
- Ataxia Telangiectasia Mutated Proteins
- Poly(ADP-ribose) Polymerase Inhibitors
- Prostatic Neoplasms, Castration-Resistant
- Mutation
- Circulating Tumor DNA